Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
32.22B
Market cap32.22B
Price-Earnings ratio
-103.08
Price-Earnings ratio-103.08
Dividend yield
Dividend yield
Average volume
1.12M
Average volume1.12M
High today
$237.34
High today$237.34
Low today
$230.96
Low today$230.96
Open price
$236.84
Open price$236.84
Volume
93.09K
Volume93.09K
52 Week high
$256.36
52 Week high$256.36
52 Week low
$125.38
52 Week low$125.38

Stock Snapshot

The current Natera(NTRA) stock price is $232.96, with a market capitalization of 32.22B. The stock trades at a price-to-earnings (P/E) ratio of -103.08.

On 2026-01-13, Natera(NTRA) stock traded between a low of $230.96 and a high of $237.34. Shares are currently priced at $232.96, which is +0.9% above the low and -1.8% below the high.

Natera(NTRA) shares are trading with a volume of 93.09K, against a daily average of 1.12M.

During the past year, Natera(NTRA) stock moved between $125.38 at its lowest and $256.36 at its peak.

During the past year, Natera(NTRA) stock moved between $125.38 at its lowest and $256.36 at its peak.

NTRA News

TipRanks 12h
Natera: Accelerating MRD Momentum, Revenue Outperformance, and Improving Cash Profile Support Buy Rating

Kallum Titchmarsh, an analyst from Morgan Stanley, maintained the Buy rating on Natera. The associated price target remains the same with $265.00. Claim 70% Off...

TipRanks 1d
Nvidia enters collaboration with Natera

Natera (NTRA) announced a new collaboration with NVIDIA (NVDA) to accelerate the development of Natera’s multimodal AI foundation model platform and expand appl...

TipRanks 1d
Natera reports preliminary Q4 revenue $660M, consensus $577.62M

Reports preliminary FY25 revenue $2.3B, consensus $2.22B. Approximately 923,600 tests were processed in the fourth quarter compared to 792,800 tests in the four...

Analyst ratings

87%

of 23 ratings
Buy
87%
Hold
13%
Sell
0%

More NTRA News

Simply Wall St 5d
Assessing Natera Valuation After Positive ALTAIR Trial Data And Expanded Fetal Focus Test Launch

Natera (NTRA) has drawn fresh attention after new ALTAIR phase III data showed a statistically significant disease free survival benefit for Signatera positive...

Assessing Natera Valuation After Positive ALTAIR Trial Data And Expanded Fetal Focus Test Launch
Nasdaq 6d
NTRA Crosses Above Average Analyst Target

In recent trading, shares of Natera Inc (Symbol: NTRA) have crossed above the average analyst 12-month target price of $74.07, changing hands for $74.19/share....

NTRA Crosses Above Average Analyst Target

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.